The Catholic University of Korea, Yeouido St.Mary's Hospital

Seoul 7345

6 studies enrolling now · 26 studies all time

What they study most

Advanced Solid Tumor, Agitation, Alzheimer Disease, Alzheimer's Disease, Anhedonia, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Diffuse Large B Cell Lymphoma, Diffuse Large B-cell Lymphoma

Studies at this site

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease — Recruiting now
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight — Completed
• Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide — Running, not enrolling
• RegoNivo vs Standard of Care Chemotherapy in AGOC — Completed
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
• A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Completed
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients — Running, not enrolling
• Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — Running, not enrolling
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Running, not enrolling
• Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma — Completed
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 — Completed
• A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD — Completed
• A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer — Status unconfirmed
• A Phase II Study of M2951 in SLE — Stopped early
• A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments — Completed